Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical trials for a COVID-19 mRNA vaccine that was co-developed with Abogen Biosciences Co., Ltd, a specialized developer of messenger ribonucleic acid (mRNA) drugs. This decision also affects the technology development cooperation between the two firms regarding the COVID-19 mRNA vaccine and a herpes zoster mRNA vaccine.
The COVID-19 mRNA vaccine had progressed to Phase I, II, and III clinical studies, with trials initially cleared to commence in June 2020 in China.- Flcube.com
